UCB acquisition (validated superior to EI across 6/6 drug-discovery targets) will outperform EI in multi-objective mRNA sequence optimisation because synonymous codon spaces share the high-uncertainty, sparse-reward topology that UCB's exploration bonus is empirically suited to exploit, predicting a ≥15% improvement in Pareto-front coverage over EI at equivalent oracle call budgets.

BiologyAug 21, 2026Evaluation Score: 71%

Adversarial Debate Score

75% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Grok: {"code":"permission-denied","error":"Your team 66dc1710-5e0c-42e8-bdea-258e945fcd69 has either used all available credits or reached its monthly spending limit. To co...

ChatGPT: The hypothesis is clearly falsifiable and gains credible support from validated 6/6-target UCB superiority, but the transfer from drug-discovery BO to discrete, multi-objective synonymous-codon search is not directly established. The claimed shared topology and ≥15% Pareto-coverage gain remain un...

Claude: The hypothesis rests on a genuinely validated finding (UCB outperforming EI across 6/6 drug-discovery targets in the owner's own experiments), and the mechanistic analogy to synonymous codon space topology is scientifically plausible; however, the extrapolation from single-objective drug-discover...

Mistral: The hypothesis is well-grounded in the owner’s validated experiments (UCB’s superiority in drug-discovery BO) and aligns with the sparse-reward, high-uncertainty topology of mRNA codon spaces, but its generalizability to multi-objective mRNA optimization lacks direct empirical support from the pr...

Supporting Research Papers

Sampling-based Continuous Optimization for Messenger RNA Design
Designing messenger RNA (mRNA) sequences for a fixed target protein requires searching an exponentially large synonymous space while optimizing properties that affect stability and downstream performa...
Budget-Sensitive Discovery Scoring: A Formally Verified Framework for Evaluating AI-Guided Scientific Selection
Scientific discovery increasingly relies on AI systems to select candidates for expensive experimental validation, yet no principled, budget-aware evaluation framework exists for comparing selection s...
Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction ...
ELISA: An Interpretable Hybrid Generative AI Agent for Expression-Grounded Discovery in Single-Cell Genomics
Translating single-cell RNA sequencing (scRNA-seq) data into mechanistic biological hypotheses remains a critical bottleneck, as agentic AI systems lack direct access to transcriptomic representations...

Computational Result

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

UCB's advantages in high-uncertainty spaces remain to be fully validated in mRNA optimization.

Method: literature_meta · Result: inconclusive · Confidence: 60%

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

In a fixed-budget, multi-objective Bayesian optimization loop over synonymous-codon mRNA sequence space — where objectives include at minimum predicted translation efficiency, mRNA stability (minimum free energy / degradation score), and immunogenicity/off-target score — Upper Confidence Bound (UCB) acquisition, with exploration coefficient β tuned via standard Gaussian-process-UCB regret bounds (e.g., β_t = 2 log(|D|t²π²/6δ)), will achieve ≥15% greater hypervolume-normalized Pareto-front coverage than Expected Improvement (EI, including its multi-objective variants EHVI/qEHVI) at equivalent oracle call budgets (N = 50, 100, 250, 500 calls), averaged over ≥5 independent target proteins/UTR contexts and ≥10 random seeds per condition, with statistical significance at p<0.05 (paired Wilcoxon signed-rank, Holm-Bonferroni corrected across budgets).

Disproof criteria:

UCB shows <15% hypervolume improvement over EI (including negative or null results) across the majority (≥3/5) of target proteins/contexts tested, at matched budgets.
Improvement is present but not statistically significant (p≥0.05 after correction) across seeds.
Improvement is budget-dependent in a way that contradicts the "equivalent oracle call budget" framing — e.g., UCB only wins at N≥500 (large budget) but hypothesis is framed as budget-equivalent generalizable advantage.
Effect disappears or reverses when using a properly calibrated multi-objective EI variant (qNEHVI, qLogNEHVI) rather than naive scalarized EI — this would indicate the "6/6 target" prior result used a weak EI baseline, invalidating the generalization claim.
Effect is fully explained by hyperparameter mistuning of EI's exploration-exploitation trade-off (e.g., ξ parameter) rather than a genuine UCB structural advantage.

Spine & Adversarial Read

highThe foundational premise — 'UCB validated superior to EI across 6/6 drug-discovery targets' — has no citable source, no methodology detail, and no confirmation that the EI baseline used was competently tuned or that 6 targets constitutes a generalizable sample. The entire hypothesis is built on an unverified, unreplicated internal claim being extrapolated across domains (small molecules → mRNA codons) without independent evidence the topological analogy holds.
This EVP explicitly treats the '6/6 targets' claim as an unverified prior (see EXTERNAL_CONFLICTS) and does not depend on it being true — the protocol re-derives the UCB vs. EI comparison from scratch on mRNA tasks with proper baselines (including qNEHVI, the modern multi-objective standard, not just naive EI). However, the EVP does not independently validate the original 6/6 claim itself; that gap remains unresolved and should be flagged in any final report as an unverified premise, not a validated foundation.
mediumWhy compare against EI/EHVI/qNEHVI specifically and not other strong sparse-reward exploration baselines such as Thompson Sampling, entropy search (MES/JES), or evolutionary algorithms (CMA-ES, genetic algorithms) commonly used in real mRNA codon optimization pipelines? If UCB's advantage disappears against Thompson Sampling or a well-tuned genetic algorithm, the practical claim ('UCB should be adopted') is much weaker even if the narrow UCB-vs-EI comparison succeeds.
The methodology (step 4, implementation sketch) does include Thompson Sampling and Random as baselines for context, partially addressing this. However the primary/success criteria are scoped narrowly to UCB vs. EI-family only, matching the stated hypothesis — this is a deliberate scope decision, but it should be stated explicitly in any publication that the finding (if positive) supports 'UCB > EI' specifically, not 'UCB is the best available method for mRNA design,' since GA/evolutionary baselines are not part of the primary comparison.
highPurely in silico oracle-based validation (using learned predictors for translation efficiency, stability, immunogenicity) cannot establish that the optimized sequences are actually better therapeutics — oracle models have their own blind spots and biases, and an acquisition function that better exploits oracle idiosyncrasies is not the same as one that finds biologically superior sequences.
Explicitly acknowledged as a limitation (KNOWN_FAILURE_MODES). This EVP is scoped as an in silico algorithmic validation only; it does not include wet-lab synthesis/expression confirmation of top Pareto-front candidates, which would be a necessary follow-up (and separate, costlier EVP) before any claim of therapeutic relevance. The current package validates the optimization-algorithm claim, not the biological-design claim, and this distinction must be preserved in reporting.

Experimental Protocol

Design: Head-to-head benchmark, within-subject (same surrogate model class, same oracle, same initial design) comparing UCB vs. EI/EHVI/qNEHVI acquisition functions across a matrix of {oracle task} × {budget} × {seed}.

Factors: Acquisition function (UCB, EI, EHVI, qNEHVI, random baseline, Thompson Sampling baseline) × Budget (50, 100, 250, 500 oracle calls) × Task (5 target proteins spanning different length/GC-content regimes) × Seed (10 replicates)
Total runs: 6 acquisitions × 4 budgets × 5 tasks × 10 seeds = 1,200 optimization runs
Primary outcome: Normalized hypervolume of Pareto front at each budget checkpoint, relative to a reference point and an estimated true Pareto front (computed via exhaustive/near-exhaustive search on small tasks, or a very-large-budget consensus front on larger tasks).
Secondary outcomes: Pareto front size, generational distance, spread/diversity (crowding distance), wall-clock/computational overhead per acquisition step.

Required datasets:

Oracle models (must be pre-existing, validated predictors — not trained fresh, to avoid confounding oracle quality with acquisition performance):
- Translation efficiency: existing CDS/5'UTR ribosome-load models (e.g., Optimus 5-Prime, or in-house TE predictor)
- mRNA stability/degradation: RNA degradation prediction model (e.g., Stanford OpenVaccine COVID-19 mRNA degradation dataset + trained GNN/transformer)
- Immunogenicity/off-target: codon usage bias + CpG/UpA dinucleotide frequency scorers, or innate immune activation predictors
Sequence space definition: 5 target CDS regions (e.g., SARS-CoV-2 spike RBD, EPO, erythropoietin, a monoclonal antibody heavy chain fragment, luciferase reporter) with full synonymous codon table per species (human-optimized codon usage table, CoCoPUTs database)
Benchmark libraries: BoTorch/Ax (for qNEHVI, qEHVI implementations), GPyTorch (GP surrogate), a custom UCB implementation matched in surrogate architecture
Ground truth for small-scale validation: exhaustive enumeration on short synonymous blocks (≤15 codons, ~14M combinations) to compute true Pareto front for calibration
Compute environment: containerized Python 3.11, BoTorch ≥0.10, GPyTorch, RDKit-analogue for sequence encoding (custom one-hot/embedding codon encoder)

Success:

Primary: UCB achieves ≥15% relative hypervolume-coverage improvement over the best-performing EI variant (of EI, EHVI, qNEHVI) at N=100 calls, averaged across 5 tasks, with p<0.05 (Holm-Bonferroni corrected).
Secondary: Effect direction (UCB > EI) replicates in ≥4/5 individual tasks (not just in aggregate).
Robustness: Effect persists (≥10% improvement) across at least 2 of 3 surrogate architectures tested.
Effect is not attributable to EI hyperparameter mistuning (ablation in step 11 shows properly-tuned EI still underperforms).

Failure:

UCB improvement <15% or not statistically significant at N=100 primary endpoint.
Effect reverses (EI outperforms UCB) in ≥2/5 tasks, indicating task-dependence that undermines the general claim.
Effect vanishes when compared against qNEHVI specifically (the modern, properly multi-objective EI variant) — this would indicate the original "6/6 targets" finding used an outdated/weak EI baseline.
Oracle validation (step 3) shows oracle R²<0.4, indicating results would not be trustworthy regardless of acquisition function comparison (abort trigger, not just failure).

ROI Projection

Implementation Sketch

for task in [target_1, ..., target_5]:
    oracle = load_validated_oracle_ensemble(task)  # TE, stability, immunogenicity
    codon_space = enumerate_synonymous_space(task.cds)

    for acquisition in [UCB, EI, EHVI, qNEHVI, Random, ThompsonSampling]:
        for seed in range(10):
            X_init = random_sample(codon_space, n=10, seed=seed)
            Y_init = oracle.batch_score(X_init)
            surrogate = fit_GP(X_init, Y_init)

            history = []
            for call in range(budget_max):
                if acquisition == UCB:
                    beta_t = 2 * log(len(codon_space) * (call+1)**2 * pi**2 / (6*0.05))
                    x_next = argmax_{x in codon_space} (mu(x) + sqrt(beta_t) * sigma(x))
                else:
                    x_next = acquisition.propose(surrogate, codon_space, Y_init)

                y_next = oracle.score(x_next)
                X_init, Y_init = append(X_init, x_next), append(Y_init, y_next)
                surrogate = update_GP(surrogate, X_init, Y_init)

                if call in checkpoints:  # 25, 50, 100, 250, 500
                    pf = compute_pareto_front(Y_init)
                    hv = compute_hypervolume(pf, ref_point=task.ref_point)
                    history.append((call, acquisition, seed, hv))

            save(history)

# analysis
df = aggregate_all(histories)
for budget in checkpoints:
    for task in tasks:
        wilcoxon_test(df[UCB][budget][task], df[best_EI_variant][budget][task])
holm_bonferroni_correct(all_pvalues)
report(hypervolume_ratio, ci95, pvalues)

Abort checkpoints:

After oracle validation (Day 5): if any oracle R²<0.4 against held-out ground truth, halt and re-select/retrain oracle before proceeding — results built on unreliable oracles are worthless.
After small-scale exhaustive calibration (Day 10): if GP surrogate hypervolume-coverage on the ≤15-codon exhaustive task is <50% for ALL acquisition functions (including random), this indicates a surrogate/encoding bug, not an acquisition function signal — halt and debug.
After first 2 tasks complete (Day 20): if UCB shows no directional advantage (even non-significant trend) in either of the first 2 tasks, consider stopping before completing all 5 tasks — early null result strongly predicts full null result given the internal 6/6 prior claim is unverified.
Mid-analysis (Day 28): if properly-tuned qNEHVI outperforms UCB in aggregate, deprioritize further runs and pivot report toward "EI variant choice matters more than UCB vs EI" framing.

NAMED_EXPERTS: []

CLOSEST_EXISTING_WORK: []

NOVELTY_NARROWING_REQUIRED: false

SPINE_STATEMENT: This hypothesis tests whether UCB acquisition achieves at least 15% greater Pareto-front hypervolume coverage than Expected Improvement (and its multi-objective variants) at matched oracle-call budgets in multi-objective synonymous-codon mRNA sequence optimization.

Source

AegisMind Research

Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started